Scholarlink

Introduction <p>Although Chronic Hand Eczema (CHE) is associated with substantial humanistic burden, treatment patterns and economic impact are poorly understood in the USA. Therefore, this study characterized real-world treatment patterns and economic burden among patients with moderate&#xa0;to&#xa0;severe CHE in the USA.</p> Methods <p>US claims data (01/2016–04/2024) were used to identify adults with moderate&#xa0;to&#xa0;severe CHE. Treatments were assessed post-diagnosis, with patients stratified into non-mutually exclusive cohorts on the basis of eczema/dermatitis-related treatment received. Eczema/dermatitis-related healthcare resource utilization and costs were descriptively reported while on treatment.</p> Results <p>In total, 6295 patients with moderate&#xa0;to&#xa0;severe CHE were included (mean age: 48.2&#xa0;years; 63.8% female; 76.6% commercially insured). Topical and systemic corticosteroid therapies were used by 81.3% and 86.2% of patients, respectively. Treatment patterns were heterogeneous; patients frequently transitioned between systemic, topical, and no treatment. Total eczema/dermatitis-related costs per-person-per-year increased with treatment intensity, to $21,682 among patients receiving monoclonal antibodies/oral Janus kinase inhibitors.</p> Conclusions <p>Substantial disease heterogeneity, extensive corticosteroid reliance, and steep increases in healthcare costs with treatment escalation were observed, underscoring an urgent need for CHE-specific therapies capable of providing durable control and reducing inappropriate resource use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月24日

查看全文
  • April W. Armstrong,
  • Rebecca Burne,
  • Aseel Bin Sawad,
  • Anais Lemyre,
  • Marjolaine Gauthier-Loiselle,
  • Annie Guerin,
  • Tanzania Vinson,
  • Brent Milovac,
  • Sanjeev Balu

摘要

Introduction

Although Chronic Hand Eczema (CHE) is associated with substantial humanistic burden, treatment patterns and economic impact are poorly understood in the USA. Therefore, this study characterized real-world treatment patterns and economic burden among patients with moderate to severe CHE in the USA.

Methods

US claims data (01/2016–04/2024) were used to identify adults with moderate to severe CHE. Treatments were assessed post-diagnosis, with patients stratified into non-mutually exclusive cohorts on the basis of eczema/dermatitis-related treatment received. Eczema/dermatitis-related healthcare resource utilization and costs were descriptively reported while on treatment.

Results

In total, 6295 patients with moderate to severe CHE were included (mean age: 48.2 years; 63.8% female; 76.6% commercially insured). Topical and systemic corticosteroid therapies were used by 81.3% and 86.2% of patients, respectively. Treatment patterns were heterogeneous; patients frequently transitioned between systemic, topical, and no treatment. Total eczema/dermatitis-related costs per-person-per-year increased with treatment intensity, to $21,682 among patients receiving monoclonal antibodies/oral Janus kinase inhibitors.

Conclusions

Substantial disease heterogeneity, extensive corticosteroid reliance, and steep increases in healthcare costs with treatment escalation were observed, underscoring an urgent need for CHE-specific therapies capable of providing durable control and reducing inappropriate resource use.